A comparative cross-sectional study of Chinese and American lung caner drug trial in 2019_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

WANG Shuhang , FANG Yuan , HUANG Huiyao , WU Dawei , YU Yue ,  LI Ning

National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.R.China;

Corresponding author：

LI Ning, Email: lining@cicams.ac.cn

Keywords：

Lung cancer; clinical studies; China versus the United States; primary tested drug ratio; target abundance

DOI：

10.7507/1007-4848.201912032

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To compare the current status of clinical studies regarding lung cancer between China and the United States in 2019, and to indicate the weakness, trend and future development direction of clinical studies drug treatment in China.Methods The data of lung cancer clinical studies from January 1st to November 30th, 2019 in China and the United States were retrieved and analyzed through Informa pharmaprojects database.Results The United States was superior on the number of projects (128 vs. 156) and research institutions (743 vs. 2 250). Compared with the United State, there were more phase Ⅲ confirmatory researches (19.5% vs. 10.3%), bioequivalent drug researches (3.1% vs. 0%), and researches initiated by academic institutions (39.8% vs. 28.1%) in China. The United States exhibited advantages in phaseⅠ andⅠ/Ⅱstudies (25.8% vs. 60.3%), immunodrugs (49.2% vs. 60.3%), primary tested drug ratio (61.7% vs. 93.6%), targets abundance (32.9% vs. 69.6%), and chimeric antigen receptor-T (CAR-T, 0.7% vs. 7.1%).Conclusion Compared with the United States, China should pay more attention to innovative drug investigations in early phase of clinical studies, especially novel immune agents, vaccines, and CAR-T.

Citation： WANG Shuhang, FANG Yuan, HUANG Huiyao, WU Dawei, YU Yue, LI Ning. A comparative cross-sectional study of Chinese and American lung caner drug trial in 2019. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(3): 327-331. doi: 10.7507/1007-4848.201912032 Copy

1.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin, 2016, 66(1): 7-30.
2.	Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
3.	Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial. J Thorac Oncol, 2019, 14(5): 867-875.
4.	Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase Ⅱtrial (ALTER0302). Br J Cancer, 2018, 118(5): 654-661.
5.	Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol, 2019, 20(11): e619-e626.
6.	Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol, 2018, 36(17): 1675-1684.
7.	Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, 2018, 378(22): 2078-2092.
8.	Criss SD, Mooradian MJ, Sheehan DF, et al. Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage Ⅲ non-small cell lung cancer in the context of the US health care system. JAMA Oncol, 2019, 5(3): 358-365.
9.	Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res, 2019, 11: 7707-7719.
10.	Rosell R, Dafni U, Felip E, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med, 2017, 5(5): 435-444.
11.	Bang A, Schoenfeld JD, Sun AY. PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Transl Lung Cancer Res, 2019, 8(Suppl 2): S139-S146.
12.	Li N, He J, Gao SG, et al. Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable non-small cell lung cancer. 2019 WCLC, poster JCSE01.10.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin, 2016, 66(1): 7-30.
2. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
3. Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial. J Thorac Oncol, 2019, 14(5): 867-875.
4. Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase Ⅱtrial (ALTER0302). Br J Cancer, 2018, 118(5): 654-661.
5. Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol, 2019, 20(11): e619-e626.
6. Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol, 2018, 36(17): 1675-1684.
7. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, 2018, 378(22): 2078-2092.
8. Criss SD, Mooradian MJ, Sheehan DF, et al. Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage Ⅲ non-small cell lung cancer in the context of the US health care system. JAMA Oncol, 2019, 5(3): 358-365.
9. Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res, 2019, 11: 7707-7719.
10. Rosell R, Dafni U, Felip E, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med, 2017, 5(5): 435-444.
11. Bang A, Schoenfeld JD, Sun AY. PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Transl Lung Cancer Res, 2019, 8(Suppl 2): S139-S146.
12. Li N, He J, Gao SG, et al. Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable non-small cell lung cancer. 2019 WCLC, poster JCSE01.10.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

A comparative cross-sectional study of Chinese and American lung caner drug trial in 2019

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content